Get Updates

Research & Clinical Trials

FORCE has a strong commitment to promoting research to benefit our community. We advocate for more research funding, educate people about available studies, and report findings back to our community.

| More

Featured Research

For a listing of other research studies recruiting patients please visit our Active Studies page.

OlympiA
OlympiA

The OlympiA trial is the first major study to test a targeted therapy for people with BRCA mutation-associated breast cancer in the adjuvant setting (after surgery) for people with earlier-stage (stage 2 or stage 3) cancers.

Brocade3
Brocade3

Brocade3 is a research study evaluating the safety and effectiveness of an investigational medication in addition to treatment with chemotherapy for patients with metastatic or locally advanced BRCA associated, HER2-negative breast cancer. For more information, ask your doctor about the Brocade3 Study or visit www.Brocade3Study.com to see if you may qualify!

PRIMA
PRIMA

PRIMA will study whether niraparib (an investigational PARP inhibitor) works better than a placebo in maintenance therapy for women with ovarian, fallopian tube or peritoneal cancer, who have completed initial treatment and whose tumor is unable to fix damaged DNA.

QUADRA
QUADRA

A study for women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received at least 3 previous chemotherapy regimens (which may have included a PARP inhibitor).

FindMyVariant
FindMyVariant

FindMyVariant is testing a website for individuals with variants of uncertain significance who want to connect with their relatives and find more about their variant.

ABOUT Patient Powered Research Network
ABOUT Patient Powered Research Network

The ABOUT Network is the first-ever patient-powered research registry created and governed by and for people affected by HBOC.

POLO - Pancreatic Cancer Study
POLO - Pancreatic Cancer Study

POLO is a research study asking the question does maintenance therapy with olaparib (a PARP inhibitor) benefit patients with pancreas cancer associated with mutation of the BRCA gene.

Basser Research Center for BRCA
Basser Research Center for BRCA

Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center.

INFORM Study
INFORM Study

A study for newly-diagnosed breast cancer patients who carry a BRCA1 or BRCA2 mutation.

Healthy 1000
Healthy 1000

Healthy 1000 is a study to look at the utility of circulating tumor DNA in asymptomatic subjects for the detection of cancer.

BRAVO
BRAVO

A study investigating the PARP inhibitor niraparib for women with previously treated HER2 negative, BRCA positive breast cancer.

ARIEL2
ARIEL2

ARIEL2 is a Phase 2 PARP inhibitor trial for women with relapsed, high-grade serous or endometrioid ovarian cancer.

OlympiA OlympiA

The OlympiA trial is the first major study to test a targeted therapy for people with BRCA mutation-associated breast cancer in the adjuvant setting (after surgery) for people with earlier-stage (stage 2 or stage 3) cancers. 

 

View eligibility and exclusion criteria.

More Information

Brocade3 Brocade3

Brocade3 is a research study evaluating the safety and effectiveness of an investigational medication in addition to treatment with chemotherapy for patients with metastatic or locally advanced BRCA associated, HER2-negative breast cancer. For more information, ask your doctor about the Brocade3 Study or visit www.Brocade3Study.com to see if you may qualify!

More Information

PRIMA PRIMA

PRIMA will study whether niraparib (an investigational PARP inhibitor) works better than a placebo in maintenance therapy for women with ovarian, fallopian tube or peritoneal cancer, who have completed initial treatment and whose tumor is unable to fix damaged DNA. Participants will have completed at least 4 cycles of initial platinum-based chemotherapy and have tumors that are homologous recombination deficient (HRD) positive, which typically includes tumors in women with BRCA or other inherited mutations. 

 

 

 

More Information

QUADRA QUADRA

QUADRA is a study for women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received at least 3 previous chemotherapy regimens (which may have included a PARP inhibitor). The study will evaluate the antitumor activity of niraparib (an oral PARP inhibitor).  Women with and without germline BRCA mutations can participate, and testing will be done as part of the study.   All participants will receive niraparib.  

For more information visit:

www.tesarobio.com or Clinicaltrials.gov

More Information

FindMyVariant FindMyVariant

FindMyVariant is testing a web tool that provides resources for individuals with variants of uncertain significance.  Study participants can use the web tool to connect with their relatives and see how tracing a variant traveling through a family can give more information about what the variant means.

More Information

ABOUT Patient Powered Research Network ABOUT Patient Powered Research Network

ABOUT is the first ever research registry created and governed byand for people affected by HBOC. The ABOUT Network is a "patient-powered" research registry and one of only 29 networks chosen for participation in the National Patient Centered Outcomes Research Network (known as PCORnet). Our goal is to enroll as many Americans with HBOC as possible into our research registry and to collect information and real world health care experiences that can be used along with information from medical records to improve care for people with HBOC.

More Information

POLO - Pancreatic Cancer Study POLO - Pancreatic Cancer Study

POLO is a research study asking the question does maintenance therapy with olaparib (a PARP inhibitor) benefit  patients with  pancreas cancer associated with mutation of the BRCA gene whose tumor has not grown on an  initial platinum containing drug regimen but who would otherwise be now getting  a break or pause  in their chemotherapy.

More Information

Basser Research Center for BRCA Basser Research Center for BRCA

Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center. 

More Information

INFORM Study INFORM Study

INFORM is a study for patients newly diagnosed with breast cancer who have a BRCA1 or BRCA2 mutation. The study is evaluating whether the chemotherapy drug cisplatin is better than currently used standard chemotherapy drugs (Cyclophosphamide/Doxorubicin) for treating patients with newly diagnosed breast cancer due to an inherited abnormality (mutation) in one of the breast cancer genes, BRCA1 or BRCA2. 

More Information

Healthy 1000 Healthy 1000

Pathway Genomics has developed an experimental assay that will detect circulating tumor DNA examining well-studied mutations in genes associated with the development and progression of cancer. The study investigates the utility of ctDNA in asymptomatic subjects for the detection of cancer. To participate, you must not have received a personal diagnosis in the past, and be over the age of 50, or if between 18-50 years old, be at a known increased risk for breast, ovarian, colon, lung, pancreatic, or thyroid cancers, or melanoma. Visit www.pathway.com/healthy1000/ or https://clinicaltrials.gov/ct2/show/record/NCT02612350

More Information

BRAVO BRAVO

BRAVO is a trial for men and women who have HER2 negative, BRCA mutation positive (hereditary) breast cancer that has progressed after previous treatment. The study will look at how well niraparib (a PARP inhibitor) works compared with standard chemotherapy. Patients will be randomized 2 to 1 so that two patients will take niraparib and one will take their doctor’s choice of chemotherapy. Collaborators for this international trial include the Breast International Group (BIG) and the European Organisation for Research and Treatment of Cancer (EORTC).

Visit clinicaltrials.gov at: http://clinicaltrials.gov/ct2/show/NCT01905592 or http://www.tesarobio.com


 

More Information

ARIEL2 ARIEL2

ARIEL2 is a Phase 2 PARP inhibitor trial for women with relapsed, high-grade serous or endometrioid ovarian cancer.  ARIEL2 is now enrolling its expansion phase to include patients who have failed three lines of prior chemotherapy and are platinum sensitive or platinum resistant.  All patients enrolled in the study will receive the PARP inhibitor rucaparib.

More Information

Learn about the latest breakthroughs in research and our ABOUT Network.

Featured Research

With input from our Scientific Advisory Board, FORCE critically evaluates new research articles on topics of interest to our community and makes the science understandable and accessible to our community.

Join the ABOUT Network

The goal of the ABOUT network is to enroll as many Americans with HBOC risk as possible into our research registry and to collect information and real world health care experiences that can be used along with information from medical records to improve care for people with HBOC.

FORCE:Facing Our Risk of Cancer Empowered